OXB to present at the Leerink
Partners Global Healthcare Conference
Oxford, UK - 26 February 2025: OXB (LSE: OXB), a global quality and innovation-led cell and
gene therapy CDMO, today announces that Dr.
Lucinda Crabtree, Chief Financial Officer, will take part in a
fireside chat at the Leerink Partners Global Healthcare Conference
in Miami, Florida on Tuesday, 11 March 2025 at 2:20
PM EDT / 6:20 PM GMT.
A live webcast of the fireside chat
will be available on the 'Investor Relations' section of OXB's
website under 'Results, Reports, Presentations & Webcasts'
at www.oxb.com. A
replay will be accessible following the event.
-Ends-
Enquiries:
OXB:
Sophia Bolhassan, Head of Investor
Relations - T: +44 (0) 1865 509 737 / E: ir@oxb.com
ICR
Healthcare:
T: +44 (0)20 3709 5700 /
E: oxb@icrhealthcare.com
Mary-Jane Elliott / Angela Gray /
Davide Salvi
About OXB
OXB (LSE: OXB) is a
global quality and
innovation-led contract development and manufacturing organisation
(CDMO) in cell and gene therapy with a mission to enable its
clients to deliver life changing therapies to patients around the
world.
One of the original
pioneers in cell and gene therapy, OXB has
30 years of experience in
viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise
in lentivirus, adeno-associated virus (AAV), adenovirus and other
viral vector types. OXB's world-class capabilities span from
early-stage
development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.
OXB offers a vast number of unique
technologies for viral vector manufacturing, including a 4th
generation lentiviral vector system (the TetraVecta™ system), dual plasmid system
for AAV production, suspension and perfusion process using process
enhancers and stable producer and packaging cell lines.
OXB, a FTSE4Good constituent, is
headquartered in Oxford, UK. It has bioprocessing and
manufacturing facilities across Oxfordshire, UK,
Lyon and Strasbourg, France and near Boston, MA, US. Learn more
at www.oxb.com, and follow us on LinkedIn
and YouTube.
